PE20110302A1 - Formulacion farmaceutica de un anticuerpo contra p-selectina - Google Patents
Formulacion farmaceutica de un anticuerpo contra p-selectinaInfo
- Publication number
- PE20110302A1 PE20110302A1 PE2011000614A PE2011000614A PE20110302A1 PE 20110302 A1 PE20110302 A1 PE 20110302A1 PE 2011000614 A PE2011000614 A PE 2011000614A PE 2011000614 A PE2011000614 A PE 2011000614A PE 20110302 A1 PE20110302 A1 PE 20110302A1
- Authority
- PE
- Peru
- Prior art keywords
- selectin
- antibody against
- pharmaceutical formulation
- composition
- amount
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 239000012931 lyophilized formulation Substances 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA QUE COMPRENDE: A) UN ANTICUERPO CONTRA P-SELECTINA TAL COMO huMAb-P-SELECTINA QUE SE ENCUENTRA EN UNA CANTIDAD DE 1 A 200 MG/ML EN LA COMPOSICION; B) UN REGULADOR DE PH TAL COMO HISTIDINA EN UNA CANTIDAD DE 1 A 100 mM; C) UN AGENTE TENSIOACTIVO TAL COMO POLISORBATO EN UNA CANTIDAD DE 0.001 A 1% DE LA COMPOSICION; Y D) DE 10 A 500 mM DE UN ESTABILIZADOR O DE 5 A 500 mM DE UN AGENTE DE TONICIDAD TAL COMO TREHALOSA. DICHA COMPOSICION ES UNA FORMULACION LIQUIDA O LIOFILIZADA QUE TIENE UN PH DE 4.0 A 7.0 SIENDO UTIL EN EL TRATAMIENTO DE ASMA O ALERGIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08164746 | 2008-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110302A1 true PE20110302A1 (es) | 2011-05-21 |
Family
ID=41231968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000614A PE20110302A1 (es) | 2008-09-19 | 2009-09-09 | Formulacion farmaceutica de un anticuerpo contra p-selectina |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20100074903A1 (es) |
| EP (1) | EP2328559B1 (es) |
| JP (2) | JP5524967B2 (es) |
| KR (2) | KR20110047232A (es) |
| CN (1) | CN102159194A (es) |
| AU (1) | AU2009294680A1 (es) |
| BR (1) | BRPI0918419A2 (es) |
| CA (1) | CA2736198A1 (es) |
| CL (1) | CL2011000561A1 (es) |
| ES (1) | ES2531385T3 (es) |
| IL (1) | IL211190A0 (es) |
| MX (1) | MX2011002402A (es) |
| PE (1) | PE20110302A1 (es) |
| SG (1) | SG2014011365A (es) |
| WO (1) | WO2010031720A2 (es) |
| ZA (1) | ZA201101343B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07110370B2 (ja) | 1986-08-13 | 1995-11-29 | 昭和アルミニウム株式会社 | 温度制御自在な押出機のコンテナ |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US9795674B2 (en) | 2010-02-26 | 2017-10-24 | Novo Nordisk A/S | Stable antibody containing compositions |
| CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
| MY158130A (en) * | 2010-10-06 | 2016-08-30 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor )il-4r) antibodies |
| PH12013501576A1 (en) | 2011-01-28 | 2013-09-30 | Sanofi Biotechnology | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HK1198689A1 (en) | 2011-10-25 | 2015-05-29 | Prothena Biosciences Limited | Antibody formulations and methods |
| AR090244A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Formulacion de anticuerpo anti-selectina p |
| EP2968538A1 (en) * | 2013-03-15 | 2016-01-20 | Bayer HealthCare LLC | Anti-prolactin receptor antibody formulations |
| CN113350278B (zh) * | 2013-10-24 | 2023-03-24 | 阿斯利康(瑞典)有限公司 | 稳定的水性抗体配制品 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CA2995645A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
| EP4606820A3 (en) * | 2015-11-30 | 2025-10-29 | Medimmune, LLC | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| WO2017132827A1 (en) * | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017220988A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CA3049857A1 (en) | 2017-01-11 | 2018-07-19 | Celltrion Inc. | Stable liquid formulation |
| CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
| CN116963775A (zh) * | 2021-03-03 | 2023-10-27 | 爱乐科斯公司 | 抗siglec-8抗体制剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800815A (en) * | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
| US4783399A (en) | 1984-05-04 | 1988-11-08 | Scripps Clinic And Research Foundation | Diagnostic system for the detection of cytomegalovirus |
| EP0606391B1 (en) | 1991-09-30 | 1998-08-05 | Biogen, Inc. | Inhibition of vascular narrowing using anti-padgem antibodies |
| DE69332881T2 (de) | 1992-05-05 | 2004-01-29 | Aeres Biomedical Ltd | Antikörper gegen p-selectin und ihre verwendung |
| DE69810481T2 (de) * | 1997-06-13 | 2003-09-25 | Genentech Inc., San Francisco | Stabilisierte antikörperformulierung |
| ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| US8188231B2 (en) * | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| NZ549872A (en) * | 2004-04-13 | 2009-09-25 | Hoffmann La Roche | Anti-P-selectin antibodies |
| EP1865986B1 (en) * | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| KR20080098504A (ko) * | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| AR064220A1 (es) * | 2006-12-11 | 2009-03-18 | Hoffmann La Roche | Formulacion liofilizada mab abeta |
-
2009
- 2009-09-09 MX MX2011002402A patent/MX2011002402A/es active IP Right Grant
- 2009-09-09 CN CN2009801368376A patent/CN102159194A/zh active Pending
- 2009-09-09 PE PE2011000614A patent/PE20110302A1/es not_active Application Discontinuation
- 2009-09-09 WO PCT/EP2009/061692 patent/WO2010031720A2/en not_active Ceased
- 2009-09-09 AU AU2009294680A patent/AU2009294680A1/en not_active Abandoned
- 2009-09-09 JP JP2011527294A patent/JP5524967B2/ja not_active Expired - Fee Related
- 2009-09-09 BR BRPI0918419A patent/BRPI0918419A2/pt not_active IP Right Cessation
- 2009-09-09 SG SG2014011365A patent/SG2014011365A/en unknown
- 2009-09-09 KR KR1020117006209A patent/KR20110047232A/ko not_active Ceased
- 2009-09-09 EP EP09782818.0A patent/EP2328559B1/en not_active Not-in-force
- 2009-09-09 ES ES09782818T patent/ES2531385T3/es active Active
- 2009-09-09 CA CA2736198A patent/CA2736198A1/en not_active Abandoned
- 2009-09-09 KR KR1020147001758A patent/KR20140019035A/ko not_active Abandoned
- 2009-09-15 US US12/559,555 patent/US20100074903A1/en not_active Abandoned
-
2011
- 2011-02-10 IL IL211190A patent/IL211190A0/en not_active IP Right Cessation
- 2011-02-18 ZA ZA2011/01343A patent/ZA201101343B/en unknown
- 2011-03-17 CL CL2011000561A patent/CL2011000561A1/es unknown
-
2012
- 2012-07-30 US US13/561,233 patent/US20120321638A1/en not_active Abandoned
-
2013
- 2013-04-01 US US13/854,254 patent/US20130209478A1/en not_active Abandoned
- 2013-09-19 US US14/031,199 patent/US20140093512A1/en not_active Abandoned
-
2014
- 2014-01-17 JP JP2014006650A patent/JP2014094958A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5524967B2 (ja) | 2014-06-18 |
| KR20110047232A (ko) | 2011-05-06 |
| EP2328559B1 (en) | 2015-01-07 |
| MX2011002402A (es) | 2011-04-05 |
| US20130209478A1 (en) | 2013-08-15 |
| WO2010031720A2 (en) | 2010-03-25 |
| JP2014094958A (ja) | 2014-05-22 |
| ES2531385T3 (es) | 2015-03-13 |
| AU2009294680A1 (en) | 2010-03-25 |
| KR20140019035A (ko) | 2014-02-13 |
| US20140093512A1 (en) | 2014-04-03 |
| EP2328559A2 (en) | 2011-06-08 |
| US20120321638A1 (en) | 2012-12-20 |
| US20100074903A1 (en) | 2010-03-25 |
| ZA201101343B (en) | 2011-11-30 |
| CN102159194A (zh) | 2011-08-17 |
| CL2011000561A1 (es) | 2011-09-02 |
| CA2736198A1 (en) | 2010-03-25 |
| JP2012502942A (ja) | 2012-02-02 |
| IL211190A0 (en) | 2011-04-28 |
| WO2010031720A3 (en) | 2010-09-23 |
| BRPI0918419A2 (pt) | 2015-11-24 |
| SG2014011365A (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110302A1 (es) | Formulacion farmaceutica de un anticuerpo contra p-selectina | |
| PE20091852A1 (es) | Formulacion farmaceutica que comprende un anticuerpo de ox40l | |
| PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
| PE20130579A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa | |
| PE20131063A1 (es) | Composicion acuosa que contiene bromhexina | |
| PH12017501118B1 (en) | Pharmaceutical composition comprising plasminogen and uses thereof | |
| GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| PE20081610A1 (es) | Formulaciones de anticuerpos anti-il-13 y usos de los mismos | |
| PE20161408A1 (es) | Composiciones de insulina de rapida accion | |
| BR112014030820A2 (pt) | formulação de anticorpos | |
| MY159156A (en) | Antibody formulation | |
| PE20081477A1 (es) | Formulacion liofilizada mab abeta | |
| MY197773A (en) | Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody | |
| PE20160681A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| EA201291125A1 (ru) | Композиции глины | |
| PE20061387A1 (es) | Composiciones inmunogenicas del virus de la gripe | |
| PE20091328A1 (es) | Formulacion de anticuerpo | |
| MX2021002935A (es) | Formulacion de anticuerpos contra csf-1r. | |
| PE20091715A1 (es) | Variantes de igf-i pegiladas y composiciones que las contienen | |
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
| ATE507818T1 (de) | Orale verabreichung eines calcitonins | |
| AR086105A1 (es) | Agentes de reduccion de la deriva de pulverizacion que comprenden tensioactivos de bajo equilibrio hidrofilo-lipofilo | |
| GB201015672D0 (en) | Improvements relating to fabric treatment compositions comprising targeted benefit agents | |
| MX2014009660A (es) | Formulacion de anticuerpo anti-selectina p. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |